About Fresenius
Data last updated:
Fresenius is a company based in Bad Homburg (Germany) founded in 1912 by Eduard Fresenius. Fresenius has raised $50 million across 2 funding rounds from investors including Elliott Management and DW Management Services. The company has 37 employees as of April 06, 2024. Fresenius has completed 6 acquisitions, including APP Pharma, Eugin and Quirnsalud. Fresenius operates in a competitive market with competitors including Outset Medical, Hemotune, Diality, NxStage and Chongqing Shanwaishan Blood Purification Technology, among others.
- Headquarter Bad Homburg, Germany
- Employees 37 as on 06 Apr, 2024
- Founders Eduard Fresenius
- Stage Public
- SectorsHealthcare
- EmailLocked
- PhoneLocked
- WebsiteLocked
- SocialLocked
- Legal Name Fresenius Se & Co. Kgaa
- Annual Revenue$1.59 M (USD)220.39as on Mar 31, 2023
- Net Profit$156.23 K (USD)237.11as on Mar 31, 2023
- EBITDA$371.79 K (USD)369.6as on Mar 31, 2023
- Total Equity Funding$50 M (USD)
in 2 rounds
- Latest Funding RoundNot available
- InvestorsElliott Management
& 1 more
- Employee Count37
as on Apr 06, 2024
- Investments & AcquisitionsAPP Pharma
& 5 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Fresenius
Fresenius is a publicly listed company on the XETR with ticker symbol FRE in Germany, operating in the Health services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Fresenius
Unlock access to complete
Unlock access to complete
Funding Insights of Fresenius
Fresenius has successfully raised a total of $50M across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Fresenius
Fresenius has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include Elliott Management and DW Management Services.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | Locked | Locked | Locked | |
Multiple sectors are invested in by the hedge fund. | Locked | Locked | Locked |
Investor details for Fresenius
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Fresenius
Fresenius has strategically engaged in corporate development activities, having acquired 6 companies. Notable acquisitions include APP Pharma, Eugin and Quirnsalud.
Investment portfolio details for Fresenius
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
Multispecialty hospital services are provided through a network. | Locked | Locked | 2015 | Locked | |
Injectable pharmaceuticals are manufactured and distributed by APP Pharma. | Locked | Locked | 2002 | Locked | |
Dialysis clinics are operated nationwide in the United States. | Locked | Locked | 2002 | Locked |
Complete acquisition details for Fresenius
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Fresenius
Detailed financials for Fresenius
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Fresenius Comparisons
Peer comparison for Fresenius
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Fresenius
Fresenius operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Outset Medical, Hemotune, Diality, NxStage and Chongqing Shanwaishan Blood Purification Technology, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked | Hemodialysis machines with touchscreen displays are provided for medical use. | |
| Locked | Locked | Locked | Developer of a device for blood purification | |
| Locked | Locked | Locked | Developer of portable hemodialysis device | |
| Locked | Locked | Locked | Home and critical care dialysis systems | |
| Locked | Locked | Locked | Blood purification equipment for kidney failure patients is provided. |
Detailed competitors of Fresenius
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Fresenius
Complete news archive for Fresenius
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Fresenius
Fresenius was founded in 1912 and raised its 1st funding round 96 years after it was founded.
Fresenius is headquartered in Bad Homburg, Germany. It is registered at Bad Homburg, Hesse, Germany.
Stephan Sturm is the current CEO of Fresenius.
Fresenius is a funded company, having raised a total of $50M across 2 funding rounds to date.
As of Apr 06, 2024, the latest employee count at Fresenius is 37.
Annual revenue of Fresenius is $1.59M as on Mar 31, 2023.
Fresenius was established in 1912 in Bad Homburg, Germany, within the healthcare sector. Operations encompass IV drugs and fluids, clinical nutrition, biopharma, transfusion and cell therapies, and infusion systems. Expansion efforts target home dialysis treatments, while digitalization is utilized to enable personalized care. In 2022, annual revenues reached 42.71B, with a net profit of 1.44B recorded. Global reach supports therapy-focused services.
Fresenius's top competitors include Outset Medical, Diality and NxStage.
Yes, Fresenius is publicly traded on XETR under the ticker symbol FRE.
Fresenius has made 6 acquisitions, including APP Pharma, Eugin, and Quirnsalud.
Fresenius has 2 investors. Key investors include Elliott Management, and DW Management Services.
The ticker symbol of Fresenius is FRE on XETR.